TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29481458

Group type: EXPERIMENTAL
Intervention: Self-selected repetition duration (SELF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fixed repetition duration (FIX)
Number of subjects: 12
Study: 27547890

Group type: EXPERIMENTAL
Intervention: Retinal Nerve Fiber Layer Thickness (RNFLT)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Bruch's Membrane Opening Minimum Rim Width (BMO‐MRW)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Combined parameter of RNFLT and BMO‐MRW
Number of subjects: 181
Study: 24838902

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure therapy (10 cmH2O)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo with null pressure
Number of subjects: 43
Study: 22477065

Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 60% of VO(2max) for 90 min
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control trial (resting)
Number of subjects: 7
Study: 20413372

Group type: EXPERIMENTAL
Intervention: Calcipotriol plus betamethasone dipropionate gel
Number of subjects: 364

Group type: COMPARATOR
Intervention: Betamethasone dipropionate (single component in gel vehicle)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Calcipotriol (single component in gel vehicle)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Gel vehicle alone
Number of subjects: 364
Study: 17980928

Group type: EXPERIMENTAL
Intervention: Insulin glargine with or without OADs
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Prandial insulin (once-daily, twice-daily, or more than twice-daily)
Number of subjects: 686
Study: 16042796

Group type: EXPERIMENTAL
Intervention: Web-based health promotion and stress management training for six months
Number of subjects: 303

Group type: COMPARATOR
Intervention: Reference group (no intervention)
Number of subjects: 303
Study: 12270199

Group type: EXPERIMENTAL
Intervention: Onion intervention study measuring urinary quercetin levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LC‐PDA‐MS assay for dietary phytoestrogens
Number of subjects: 0
Study: 10081632

Group type: EXPERIMENTAL
Intervention: Basiliximab (40 mg, 20 mg on days 0 and 4)
Number of subjects: 40
Study: 7574046

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 30
Study: 2127562

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (50 mg 3-times daily)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg once daily)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 394280

Group type: EXPERIMENTAL
Intervention: Diclofenac (25 mg, three times daily for the first week, then four or six tablets in the second week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diclofenac and Placebo
Number of subjects: 44
Study: 31452437

Group type: EXPERIMENTAL
Intervention: Gene signature model (including T stage, N stage, HPV status, and gene signature)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Gene signature model
Number of subjects: 262
Study: 27628045

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 60,000 units 4 weekly (group 1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 60,000 units 8 weekly (group 2)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (group 3)
Number of subjects: 52
Study: 26493478

Group type: EXPERIMENTAL
Intervention: Mediterranean diet and exercise program (8-week program)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Mediterranean diet education only)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Mediterranean diet education)
Number of subjects: 20
Study: 23534003

Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse/rubber‐dam (ERR)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse/cotton roll (ERC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: self‐etching/rubber‐dam (SER)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: self‐etching/cotton roll (SEC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: rubber‐dam isolation
Number of subjects: 38

Group type: COMPARATOR
Intervention: cotton roll isolation
Number of subjects: 38
Study: 21896760

Group type: EXPERIMENTAL
Intervention: Social condition (observing the outcome of the lottery chosen by another person)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Private condition (observing the outcome of the unchosen lottery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social gains
Number of subjects: 0
Study: 19264972

Group type: EXPERIMENTAL
Intervention: Secondhand smoke (SHS) exposure for 1 hour
Number of subjects: 16
Study: 17395358

Group type: EXPERIMENTAL
Intervention: AED/CPR training and possession of the device
Number of subjects: 158

Group type: COMPARATOR
Intervention: CPR training
Number of subjects: 158
Study: 15154938

Group type: EXPERIMENTAL
Intervention: Vitamin C 2 g/day for 4 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: No anti-oxidant for 4 weeks
Number of subjects: 75
Study: 12057137

Group type: EXPERIMENTAL
Intervention: Radiation given concurrently with chemotherapy followed by three courses of combination chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional course of radiation
Number of subjects: 100
Study: 9258852

Group type: EXPERIMENTAL
Intervention: 10 maximum voluntary eccentric contractions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 30 maximum voluntary eccentric contractions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 maximum voluntary eccentric contractions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Second bout of 50 contractions
Number of subjects: 24
Study: 8490338

Group type: EXPERIMENTAL
Intervention: Adenoidectomy and ventilation tubes (grommets)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Ventilation tubes (grommets) alone
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Adenoidectomy alone
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Combination of adenoidectomy and ventilation tubes
Number of subjects: 228

Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 228
Study: 3688382

Group type: EXPERIMENTAL
Intervention: Vidisic (jelly artificial tear solution)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexpanthenol ointment
Number of subjects: 40
Study: 31733345

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU)
Number of subjects: 25871
Study: 29813159

Group type: EXPERIMENTAL
Intervention: Proxies estimating survival less than 6 months
Number of subjects: 764

Group type: COMPARATOR
Intervention: Proxies estimating survival greater than 6 months
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Proxies perceiving resident would die within 6 months
Number of subjects: 764
Study: 27280792

Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine (ASAQ)
Number of subjects: 865
Study: 24680615

Group type: EXPERIMENTAL
Intervention: Lindioil (experimental group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Olive oil (control group)
Number of subjects: 31
Study: 22971559

Group type: EXPERIMENTAL
Intervention: LMS-PA (LMS-oriented lesson plans)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (supervised free playtime)
Number of subjects: 8
Study: 20855114

Group type: EXPERIMENTAL
Intervention: 0.5 mg RBZ at baseline and months 1, 3, and 5 (group 1)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Focal or grid laser photocoagulation at baseline and month 3 if needed (group 2)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combination of 0.5 mg RBZ and focal or grid laser at baseline and month 3 (group 3)
Number of subjects: 126
Study: 18668535

Group type: EXPERIMENTAL
Intervention: rilonacept (160 mg weekly subcutaneous injections)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: rilonacept
Number of subjects: 47

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study: 15922530

Group type: EXPERIMENTAL
Intervention: Cozart amphetamine ELISA screening assay
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 12008860

Group type: EXPERIMENTAL
Intervention: St. John's Wort (Hypericum perforatum) extract (Calmigen)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride (Prozac)
Number of subjects: 70
Study: 10360845

Group type: EXPERIMENTAL
Intervention: Propofol bolus dose of 2 mg/kg or 1 mg/kg for those older than 65 years, followed by infusion of 25, 50, 100, or 200 microg x kg(‐1) x min(‐1) of propofol.
Number of subjects: 24
Study: 7655194

Group type: EXPERIMENTAL
Intervention: One-stitch technique
Number of subjects: 200

Group type: COMPARATOR
Intervention: No-stitch technique
Number of subjects: 200
Study: 1778191

Group type: EXPERIMENTAL
Intervention: Sustained release verapamil (SRV) 360 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 30
Study: 6212450

Group type: EXPERIMENTAL
Intervention: Ultrasonographical localization of the porta hepatis prior to PTC
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fine needle PTC without prior ultrasonographical localization
Number of subjects: 64
Study: 30807432

Group type: EXPERIMENTAL
Intervention: Peezy midstream collection device with castile soap wipe
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Peezy midstream collection device without castile soap wipe
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard clean catch midstream urine protocol
Number of subjects: 62
Study: 28882742

Group type: EXPERIMENTAL
Intervention: Negative news headlines
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: Conflicting news headlines
Number of subjects: 2056

Group type: COMPARATOR
Intervention: Positive news headlines
Number of subjects: 2056

Group type: COMPARATOR
Intervention: No-message
Number of subjects: 2056
Study: 26115560

Group type: EXPERIMENTAL
Intervention: Korean diet
Number of subjects: 31
Study: 24512053

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg once daily for 52 weeks
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 40 mg once daily for 52 weeks
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Tofogliflozin (doses not specified) in add-on trial
Number of subjects: 796
Study: 23216439

Group type: EXPERIMENTAL
Intervention: Substance use treatment for AAPIs
Number of subjects: 298

Group type: COMPARATOR
Intervention: Substance use treatment for non-AAPIs (control group)
Number of subjects: 298
Study: 19081092

Group type: EXPERIMENTAL
Intervention: 2.5 g L-arginine added to a fatty meal (3 ml cream/kg body weight)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fatty meal without L-arginine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2.5 g phenylalanine added to a fatty meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5 g leucine added to a fatty meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2.5 g L-arginine alone (without cream)
Number of subjects: 15
Study: 17560290

Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENOX)
Number of subjects: 15191

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 15191
Study: 15505128

Group type: EXPERIMENTAL
Intervention: MLC diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: NCEP diet
Number of subjects: 60
Study: 11506764

Group type: EXPERIMENTAL
Intervention: Longitudinal methods (Generalized Estimating Equations and Generalized Linear Mixed Models)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-naïve methods (tests of proportions and logistic regression)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Missing data strategies
Number of subjects: 0
Study: 9924223

Group type: EXPERIMENTAL
Intervention: 1% mepivacaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.33% bupivacaine
Number of subjects: 10
Study: 8044193

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3067950

Group type: EXPERIMENTAL
Intervention: Intensive glucose control using ultralente insulin as basal cover and soluble insulin at mealtimes
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (Intensive and Conventional)
Number of subjects: 38
Study: 29329551

Group type: EXPERIMENTAL
Intervention: Miniscalpel acupuncture treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NSAIDs (zaltoprofen, one oral tablet, three times a day for three weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Miniscalpel acupuncture treatment combined with NSAIDs
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (NSAIDs only)
Number of subjects: 36
Study: 28718535

Group type: EXPERIMENTAL
Intervention: Craniectomy with full dural flap opening (Group A)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Craniectomy with multidural-slits (Group B)
Number of subjects: 59
Study: 23920214

Group type: EXPERIMENTAL
Intervention: Nebulizer attached to the distal end of the Acapella
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulizer placed between the mouthpiece and the Acapella
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebulizer alone (control)
Number of subjects: 10
Study: 22776014

Group type: EXPERIMENTAL
Intervention: Teneligliptin 10 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 20057364

Group type: EXPERIMENTAL
Intervention: Gastric bypass (GBP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gastric banding (GB)
Number of subjects: 20
Study: 19033122

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus sodium glycididazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 60
Study: 15867184

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1441
Study: 12557836

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ; 25 mg/kg)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP; 25 mg/kg of the sulfadoxine component)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ; 15 mg/kg)
Number of subjects: 198
Study: 10376128

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 8866565

Group type: EXPERIMENTAL
Intervention: Family history of NIDDM (FH+)
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Male offspring of diabetic mothers
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Female offspring of diabetic mothers
Number of subjects: 2680
Study: 1757038

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (initially 100 mg daily, reduction every 3 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Vitamin B1 (100 mg thiamin daily)
Number of subjects: 38
Study: 7041939

Group type: EXPERIMENTAL
Intervention: Three cycles of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Surgery or radiotherapy (after 3 cycles of CMF)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CMF)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: CMF treatment
Number of subjects: 112
Study: 30370492

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily for 2 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 44
Study: 30899947

Group type: EXPERIMENTAL
Intervention: Low level laser combined with basic periodontal therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Basic periodontal therapy
Number of subjects: 80
Study: 27593618

Group type: EXPERIMENTAL
Intervention: NO3‐ rich beetroot juice (4000 mg/L NO3‐)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study: 24512799

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 14
Study: 22866961

Group type: EXPERIMENTAL
Intervention: Hypocaloric diets containing different levels of sucrose or high fructose corn syrup (HFCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise only group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20354448

Group type: EXPERIMENTAL
Intervention: Intrathoracic blood volume index (ITBVI, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hourly urine output (HUO, n = 15)
Number of subjects: 30
Study: 17452762

Group type: EXPERIMENTAL
Intervention: Cushing's syndrome patients
Number of subjects: 77

Group type: COMPARATOR
Intervention: Age
Number of subjects: 77
Study: 15494721

Group type: EXPERIMENTAL
Intervention: Combination of pegylated liposomal doxorubicin (PLD) 45 mg m(‐2) and paclitaxel 150 mg m(‐2), every 28 days for a total of six cycles
Number of subjects: 42
Study: 12467881

Group type: EXPERIMENTAL
Intervention: Fexofenadine (FEX)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cetirizine (CET)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Stanford Sleepiness Scale (SSS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Psychomotor performance tests
Number of subjects: 16

Group type: COMPARATOR
Intervention: PET with 11C-doxepin
Number of subjects: 16
Study: 9892050

Group type: EXPERIMENTAL
Intervention: Visual stimuli presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual response production
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual addends in Arabic numerals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual addends
Number of subjects: 0
Study: 7652069

Group type: EXPERIMENTAL
Intervention: Open release using a minimal incision
Number of subjects: 96

Group type: COMPARATOR
Intervention: Endoscopic carpal tunnel release
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both techniques (open and endoscopic)
Number of subjects: 96
Study: 2326093

Group type: EXPERIMENTAL
Intervention: Experimental pain sensitivity
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Position-dependent headache
Number of subjects: 44
Study: 355585

Group type: EXPERIMENTAL
Intervention: MPA (20 mg orally q 8 hr for 32 hr)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31356678

Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTZ) 200 or 400 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: CYP3A5 expressers
Number of subjects: 24
Study: 31451521

Group type: EXPERIMENTAL
Intervention: Intermittent low-dose ASA (81 mg daily for one week/placebo for one week)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Continuous low-dose ASA (81 mg daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low-dose ASA (both intermittent and continuous)
Number of subjects: 54
Study: 27768621

Group type: EXPERIMENTAL
Intervention: Biological mesh closure
Number of subjects: 104

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 104
Study: 26187121

Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behaviour Therapy (RO-DBT) for 7 months (individual and group treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 23948426

Group type: COMPARATOR
Intervention: Regular exercise group (core stability class including specific and global trunk exercises)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intervention group (regular exercises plus instruction on 8 specific stabilization muscles)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Regular exercise group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 33
Study: 21500490

Group type: EXPERIMENTAL
Intervention: vitaprost plus in rectal suppositoria for 1 month, then vitaprost forte for 2 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: gentos and lomefloxacin per os
Number of subjects: 70
Study: 19712593

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation (HBR)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Day hospital rehabilitation (DHR)
Number of subjects: 89
Study: 16829486

Group type: EXPERIMENTAL
Intervention: Narrative task with manipulations (recency of narrative presentation, narrative repetition, type of false-memory item, testing delay, repeated testing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated testing manipulation
Number of subjects: 0
Study: 14739739

Group type: EXPERIMENTAL
Intervention: Rhythm-control strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rate-control strategy
Number of subjects: 0
Study: 11335733

Group type: EXPERIMENTAL
Intervention: Amoxicillin (40 mg/kg/d in 3 daily doses)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (amoxicillin 45 mg/kg/d in 2 daily doses)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 9358333

Group type: EXPERIMENTAL
Intervention: Adaptive survival trials with skewed randomization based on logrank statistic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usual test statistic under proposed allocation scheme
Number of subjects: 0
Study: 7871042

Group type: EXPERIMENTAL
Intervention: Caffeine 600 mg/70 kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (0 mg caffeine)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Caffeine (all doses)
Number of subjects: 50
Study: 2876879

Group type: COMPARATOR
Intervention: Haloperidol (20 mg i.m. on the first day and 20 mg p.o. daily from day 2 to 21)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pipothiazine palmitate (100 mg i.m. on the first day and daily glass of milk with grenadine from day 2 to 21)
Number of subjects: 53
Study: 31198076

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management training (CBSM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waitlist control group (WCG)
Number of subjects: 43
Study: 29798296

Group type: EXPERIMENTAL
Intervention: Weisu granules combined with Lanqin oral solution
Number of subjects: 180

Group type: COMPARATOR
Intervention: Lanqin oral solution
Number of subjects: 180

Group type: COMPARATOR
Intervention: Esomeprazole Magnesium Enteric-coated Tablets and Lanqin oral solution
Number of subjects: 180